drug
ranibizumab
Marketedupdated 6mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval18 co-mentions · 9 sources
- drugBYOOVIZ16 co-mentions · 8 sources
- drugranibizumab SR14 co-mentions · 14 sources
- drugranibizumab biosimilar13 co-mentions · 13 sources
- companySamsung Bioepis Co Ltd8 co-mentions · 8 sources
- companyXbrane Biopharma AB5 co-mentions · 5 sources
- tagOphthalmology5 co-mentions · 5 sources
- tagBiosimilar5 co-mentions · 5 sources
indications
investigational
Diabetic Macular Edema
all catalysts(0)
nothing on the calendar yet
Trials studying ranibizumab
- phase3A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
- phase3Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- phase3A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
- phase4A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
- phase3A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- —A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- phase3A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
- phase3Extension Study for the Port Delivery System With Ranibizumab (Portal)
News(10)
- J&J bets $2.2B on Ollin’s vision loss drugThe deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.biopharma_dive · 19h ago
- J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecificJohnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.fiercebiotech · 1d ago
- Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetesWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 19d ago
- Merck reports mixed data for Lucentis competitor in diabetic macular edemaMerck’s ophthalmology candidate met the primary endpoint in a pivotal study, but the full results raise questions about the drug’s commercial prospects. Merck said last month that remigromig was no…endpoints · 1mo ago
- Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug dataBausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.biopharma_dive · 1mo ago
- Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potentialMerck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led analysts to predict “limited competitive potential” in diabetic macular ede…fiercebiotech · 1mo ago
- Kodiak skyrockets on positive study data for 2 eye drugsThe Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.biopharma_dive · 1mo ago
- Merck reveals study success, and possible safety worries, for eye drug hopefulA medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.biopharma_dive · 1mo ago
- Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emergeAnalysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.biospace · 1mo ago
- Merck sees pivotal victory for $3B eye disease prospectMerck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…fiercebiotech · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that